Replies to post #177912 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Turning what patients say into data, how to apply precision medicine, it's not the protocol or the endpoints but the way those will be adjudicated is the issue.

[mapman1010]

the new rules and office would make the review and analysis of data quicker and more thorough. worth waiting to be certain.

I must say I doubt that because there is nothing particular about the protocol or endpoints for the trials that we at last have witnessed, which required new FDA guidance or rules.